Nov 12, 2024 Press Releases
PDF Version Naples, FL – November 12, 2024 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug...
Aug 5, 2024 Press Releases
PDF Version 124I-evuzamitide (AT-01) is one of the first investigational diagnostic imaging agents to receive Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA), and the only diagnostic imaging agent that has received BTD for cardiac...
Jul 29, 2024 Press Releases
PDF Version AT-02 has been granted COMP positive opinions for orphan medicinal product designations in the EU for both ATTR and AL amyloidosis. AT-02 is the Company’s lead pan-amyloid removal therapeutic candidate in development. AT-02 is currently being evaluated in...
Oct 2, 2023 Press Releases
PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs. AT-01 demonstrated to be highly accurate, with 100% sensitivity for detection of cardiac amyloid, across three independent...
Apr 3, 2023 Press Releases
PDF Version AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrils AT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brain AT-07 (AT-04 + Brain Shuttle) demonstrated a 10-fold increase in brain penetration versus AT-04...
